Bronchoalveolar Cell Lung Cancer Completed Phase 3 Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0028477 (Bronchoalveolar Cell Lung Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00020709Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryTreatment
NCT00049543Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryTreatment